Amneal Pharmaceuticals, Inc. (AMRX) vs Immunovant, Inc. (IMVT)
A side-by-side comparison of Amneal Pharmaceuticals, Inc. and Immunovant, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMRX
Amneal Pharmaceuticals, Inc.
$20.30HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
IMVT
Immunovant, Inc.
$31.54HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — AMRX vs IMVT
growth of $100 · dividends reinvested · last 7yAMRX +194.9% (+16.7%/yr)IMVT +234.2% (+18.8%/yr)IMVT compounded faster over this window
AMRX IMVT
AMRX vs IMVT: by the numbers
- •IMVT is the larger company ($6.51B vs $6.48B market cap).
- •AMRX is profitable (5.05% net margin) while IMVT runs a net loss (-7585.86%).
Metrics side by side
Valuation
| Metric | AMRX | IMVT |
|---|---|---|
| P/E ratio | 41.64 | N/A |
| Forward P/E | 19.83 | N/A |
| P/S ratio | 2.08 | 917.39 |
| P/B ratio | 196.29 | 8.85 |
| EV / EBITDA | 15.31 | N/A |
| FCF yield | 1.28% | N/A |
Profitability
| Metric | AMRX | IMVT |
|---|---|---|
| Gross margin | 39.32% | 0.00% |
| Operating margin | 12.93% | 0.00% |
| Net margin | 5.05% | -7585.86% |
| ROE | 476.51% | -73.19% |
| ROIC | 13.45% | -76.00% |
Growth (annualized)
| Metric | AMRX | IMVT |
|---|---|---|
| Revenue CAGR (5Y) | 8.67% | N/A |
| EPS CAGR (5Y) | -17.72% | N/A |
| FCF CAGR (5Y) | -14.46% | N/A |
| Total return CAGR (5Y) | 30.25% | 29.93% |
Frequently asked
- Is AMRX or IMVT more profitable?
- AMRX runs the higher net margin — AMRX at 5.05% versus IMVT at -7585.86%.
- How have AMRX and IMVT total returns compared?
- Over the past 5 years, AMRX delivered 30.25% and IMVT delivered 29.93% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Amneal Pharmaceuticals P/E ratioAmneal Pharmaceuticals ROEImmunovant ROEAmneal Pharmaceuticals operating marginImmunovant operating marginAmneal Pharmaceuticals revenue growthImmunovant revenue growthAmneal Pharmaceuticals free cash flowImmunovant free cash flow
Amneal Pharmaceuticals & Immunovant appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.